Exhibit 10.2
[Sigma-Tau Industrie Farmaceutiche
Riunite S.p.A. Letterhead]
Sede: Viale Shakespeare, 47 – 00144
Roma
tel. +39 06 592.64.43 – +39 06
592.66.00
Stabilimento: Via Pontina km 30,400
00040 Pomezia (RM) Italia – tel. +39 06
9139
Pomezia, March 30,
2009
SciClone Pharmaceuticals,
Inc.
950 Tower Lane
Foster City, CA 94404
Attention: Friedhelm Blobel
Dear Sirs:
Re: (1)
Expanded and Amended Thymosin Alpha 1 License, Distributorship and
Supply Agreement signed by and between SciClone Pharmaceuticals
International Ltd (“SPIL”) and Sigma-Tau Industrie
Farmaceutiche Riunite S.p.A. (“STI”) on March 3,
2000 as amended (collectively, the “Thymosin Alpha License
Agreement”); and (2) Other Business Matters pertaining
to Thymosin Alpha 1 for the malignant melanoma
indication.
The undersigned hereby agree that,
upon execution hereof:
(1) SciClone Pharmaceuticals, Inc.
(“SCLN”), with the approval of its Board of Directors,
will cause SPIL, under the Thymosin Alpha 1 License Supply
Agreement, to grant STI the rights, (i) to lead all future
development activities for Thymosin Alpha 1 (as defined in the
Thymosin Alpha License Agreement) with respect to Hepatitis C Virus
indications in the Territory as defined in the Thymosin Alpha
License Agreement, at STI’s costs; provided that if
SPIL’s non-European interests will be materially affected by
any negotiations in which STI participates then SPIL will have the
right to participate in those negotiations, and (ii) to meet,
correspond, and otherwise interact with the European regulatory
agencies responsible for granting any approval necessary for the
development of Thymosin Alpha 1 for the treatment of the Hepatitis
C Virus regarding such development and any matters related thereto.
STI will keep SPIL appropriately
